Fornal C A, Martin F J, Metzler C W, Jacobs B L
Program in Neuroscience, Department of Psychology, Princeton University, Princeton, New Jersey, USA.
J Pharmacol Exp Ther. 1999 Oct;291(1):220-8.
The ability of pindolol to enhance the clinical antidepressant response to selective serotonin reuptake inhibitors (SSRIs) is generally attributed to a blockade of the feedback inhibition of serotonergic neuronal activity mediated by somatodendritic 5-hydroxytryptamine (5-HT)(1A) autoreceptors. The current study examined the ability of pindolol to restore the single-unit activity of serotonergic dorsal raphe nucleus neurons in awake cats after acute treatment with the SSRI fluoxetine. The effects of pindolol were compared with those of N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohe xanecarboxamide (WAY-100635), a selective 5-HT(1A) receptor antagonist. Systemic administration of fluoxetine (0.5 and 5 mg/kg i. v.) decreased neuronal firing rates to approximately 50 and 1%, respectively, of baseline levels. The subsequent administration of cumulative doses of (+/-)-pindolol (0.1-5 mg/kg i.v.) failed to reverse the neuronal inhibition produced by either dose of fluoxetine. In addition to lacking efficacy as an antagonist in these experiments, (+/-)-pindolol produced an additional decrease in neuronal activity in animals pretreated with the low dose of fluoxetine. The active enantiomer, (-)-pindolol (1 mg/kg i.v.), also was ineffective in restoring neuronal activity after fluoxetine. In contrast, systemic administration of WAY-100635 completely reversed the effect of fluoxetine (5 mg/kg) at low doses (0.025 mg/kg i.v.), and further elevated the firing rate of these neurons above prefluoxetine baseline levels. Overall, these results indicate that pindolol, unlike WAY-100635, lacks appreciable antagonist activity at 5-HT(1A) autoreceptors. Thus, the clinical efficacy of pindolol in augmenting the antidepressant response to SSRIs, such as fluoxetine, may be unrelated to a restoration of serotonergic neuronal activity.
吲哚洛尔增强临床对选择性5-羟色胺再摄取抑制剂(SSRI)抗抑郁反应的能力,通常归因于其对由树突-胞体5-羟色胺(5-HT)(1A)自身受体介导的5-羟色胺能神经元活动的反馈抑制的阻断作用。本研究检测了在给清醒猫急性注射SSRI氟西汀后,吲哚洛尔恢复5-羟色胺能中缝背核神经元单单位活动的能力。将吲哚洛尔的作用与N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-N-(2-吡啶基)环己烷甲酰胺(WAY-100635,一种选择性5-HT(1A)受体拮抗剂)的作用进行了比较。静脉注射氟西汀(0.5和5mg/kg)分别使神经元放电频率降至基线水平的约50%和1%。随后静脉注射累积剂量的(±)-吲哚洛尔(0.1 - 5mg/kg)未能逆转两种剂量氟西汀所产生的神经元抑制作用。除了在这些实验中作为拮抗剂缺乏效力外,(±)-吲哚洛尔在低剂量氟西汀预处理的动物中还使神经元活动进一步降低。活性对映体(-)-吲哚洛尔(静脉注射1mg/kg)在氟西汀处理后恢复神经元活动方面也无效。相反,静脉注射WAY-100635在低剂量(0.025mg/kg静脉注射)时完全逆转了氟西汀(5mg/kg)的作用,并使这些神经元的放电频率进一步升高至氟西汀处理前基线水平之上。总体而言,这些结果表明,与WAY-100635不同,吲哚洛尔在5-HT(1A)自身受体上缺乏明显的拮抗活性。因此,吲哚洛尔增强对诸如氟西汀等SSRI抗抑郁反应的临床疗效,可能与5-羟色胺能神经元活动的恢复无关。